Build Your Comparison

Side-by-side financial analysis
FORA logo
FORA
LLY logo
LLY
JPM logo
JPM
Try popular comparisons:

Stock Comparison

FORA vs LLY vs JPM

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
FORA
Forian Inc.

Medical - Healthcare Information Services

HealthcareNASDAQ • US
Market Cap$68M
5Y Perf.-78.5%
LLY
Eli Lilly and Company

Drug Manufacturers - General

HealthcareNYSE • US
Market Cap$1.04T
5Y Perf.+400.1%
JPM
JPMorgan Chase & Co.

Banks - Diversified

Financial ServicesNYSE • US
Market Cap$908.57B
5Y Perf.+105.8%

FORA vs LLY vs JPM — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
FORA logoFORA
LLY logoLLY
JPM logoJPM
IndustryMedical - Healthcare Information ServicesDrug Manufacturers - GeneralBanks - Diversified
Market Cap$68M$1.04T$908.57B
Revenue (TTM)$30M$72.25B$280.33B
Net Income (TTM)$-5M$25.27B$57.05B
Gross Margin46.8%83.5%60.0%
Operating Margin-13.4%45.9%25.9%
Forward P/E30.0x14.6x
Total Debt$12K$42.50B$942.38B
Cash & Equiv.$13M$7.16B$343.34B

FORA vs LLY vs JPMLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

FORA
LLY
JPM
StockMar 21May 26Return
Forian Inc. (FORA)10021.5-78.5%
Eli Lilly and Compa… (LLY)100500.1+400.1%
JPMorgan Chase & Co. (JPM)100205.8+105.8%

Price return only. Dividends and distributions are not included.

Quick Verdict: FORA vs LLY vs JPM

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: LLY leads in 3 of 7 categories, making it the strongest pick for profitability and margin quality and recent price momentum and sentiment. Forian Inc. is the stronger pick specifically for growth and revenue expansion and capital preservation and lower volatility. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
🥇LLY emerged as the overall leader. Track its performance:
FORA
Forian Inc.
The Defensive Pick

FORA is the clearest fit if your priority is sleep-well-at-night and defensive.

  • Lower volatility, beta 0.21, Low D/E 0.0%, current ratio 2.97x
  • Beta 0.21, current ratio 2.97x
  • 50.1% revenue growth vs JPM's 3.3%
Best for: sleep-well-at-night and defensive
LLY
Eli Lilly and Company
The Growth Play

LLY has the current edge in this matchup, primarily because of its strength in growth exposure and long-term compounding.

  • Rev growth 44.7%, EPS growth 96.0%, 3Y rev CAGR 31.7%
  • 14.5% 10Y total return vs JPM's 481.2%
  • 35.0% margin vs FORA's -17.0%
Best for: growth exposure and long-term compounding
JPM
JPMorgan Chase & Co.
The Banking Pick

JPM is the clearest fit if your priority is income & stability and valuation efficiency.

  • Dividend streak 15 yrs, beta 0.87, yield 1.8%
  • PEG 0.83 vs LLY's 1.04
  • Lower P/E (14.6x vs 30.0x), PEG 0.83 vs 1.04
Best for: income & stability and valuation efficiency
See the full category breakdown
CategoryWinnerWhy
GrowthFORA logoFORA50.1% revenue growth vs JPM's 3.3%
ValueJPM logoJPMLower P/E (14.6x vs 30.0x), PEG 0.83 vs 1.04
Quality / MarginsLLY logoLLY35.0% margin vs FORA's -17.0%
Stability / SafetyFORA logoFORABeta 0.21 vs JPM's 0.87, lower leverage
DividendsJPM logoJPM1.8% yield, 15-year raise streak, vs LLY's 0.5%, (1 stock pays no dividend)
Momentum (1Y)LLY logoLLY+40.7% vs FORA's +2.4%
Efficiency (ROA)LLY logoLLY22.7% ROA vs FORA's -11.8%, ROIC 41.8% vs -7.5%

FORA vs LLY vs JPM — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

Discover the Biotech & Healthcare Stocks Theme

These companies are key players in the Biotech & Healthcare Stocks ecosystem. See how they stack up against the rest of the sector.

Explore Theme
FORAForian Inc.
FY 2022
Information and Software
93.5%$26M
Service
5.5%$2M
Product and Service, Other
1.0%$274,256
LLYEli Lilly and Company
FY 2025
Product
93.5%$61.0B
Collaboration and Other Revenue
6.5%$4.2B
JPMJPMorgan Chase & Co.
FY 2025
Commercial And Investment Bank
43.0%$78.5B
Consumer & Community Banking
41.7%$76.0B
Asset and Wealth Management Segment
13.2%$24.1B
Segment Reporting, Reconciling Item, Corporate Nonsegment
3.9%$7.0B
Segment Reconciling Items
-1.7%$-3,134,000,000

FORA vs LLY vs JPM — Financial Metrics

Side-by-side numbers across 3 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLLLYLAGGINGFORA

Income & Cash Flow (Last 12 Months)

LLY leads this category, winning 5 of 6 comparable metrics.

JPM is the larger business by revenue, generating $280.3B annually — 9328.3x FORA's $30M. LLY is the more profitable business, keeping 35.0% of every revenue dollar as net income compared to FORA's -17.0%. On growth, LLY holds the edge at +55.5% YoY revenue growth, suggesting stronger near-term business momentum.

MetricFORA logoFORAForian Inc.LLY logoLLYEli Lilly and Com…JPM logoJPMJPMorgan Chase & …
RevenueTrailing 12 months$30M$72.2B$280.3B
EBITDAEarnings before interest/tax-$4M$34.7B$81.4B
Net IncomeAfter-tax profit-$5M$25.3B$57.0B
Free Cash FlowCash after capex$2M$13.6B$100.9B
Gross MarginGross profit ÷ Revenue+46.8%+83.5%+60.0%
Operating MarginEBIT ÷ Revenue-13.4%+45.9%+25.9%
Net MarginNet income ÷ Revenue-17.0%+35.0%+20.4%
FCF MarginFCF ÷ Revenue+7.8%+18.8%+36.0%
Rev. Growth (YoY)Latest quarter vs prior year-2.9%+55.5%
EPS Growth (YoY)Latest quarter vs prior year-2.0%+169.9%+16.0%
LLY leads this category, winning 5 of 6 comparable metrics.

Valuation Metrics

JPM leads this category, winning 4 of 7 comparable metrics.

At 16.2x trailing earnings, JPM trades at a 66% valuation discount to LLY's 47.8x P/E. Adjusting for growth (PEG ratio), JPM offers better value at 0.92x vs LLY's 1.66x — a lower PEG means you pay less per unit of expected earnings growth.

MetricFORA logoFORAForian Inc.LLY logoLLYEli Lilly and Com…JPM logoJPMJPMorgan Chase & …
Market CapShares × price$68M$1.04T$908.6B
Enterprise ValueMkt cap + debt − cash$55M$1.07T$1.51T
Trailing P/EPrice ÷ TTM EPS-23.48x47.85x16.22x
Forward P/EPrice ÷ next-FY EPS est.30.00x14.60x
PEG RatioP/E ÷ EPS growth rate1.66x0.92x
EV / EBITDAEnterprise value multiple34.32x18.52x
Price / SalesMarket cap ÷ Revenue2.24x15.92x3.25x
Price / BookPrice ÷ Book value/share2.27x37.16x2.51x
Price / FCFMarket cap ÷ FCF23.49x115.64x9.01x
JPM leads this category, winning 4 of 7 comparable metrics.

Profitability & Efficiency

LLY leads this category, winning 6 of 9 comparable metrics.

LLY delivers a 101.2% return on equity — every $100 of shareholder capital generates $101 in annual profit, vs $-17 for FORA. FORA carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to JPM's 2.60x. On the Piotroski fundamental quality scale (0–9), LLY scores 8/9 vs JPM's 5/9, reflecting strong financial health.

MetricFORA logoFORAForian Inc.LLY logoLLYEli Lilly and Com…JPM logoJPMJPMorgan Chase & …
ROE (TTM)Return on equity-17.2%+101.2%+15.9%
ROA (TTM)Return on assets-11.8%+22.7%+1.3%
ROICReturn on invested capital-7.5%+41.8%+4.5%
ROCEReturn on capital employed-8.2%+46.6%+8.9%
Piotroski ScoreFundamental quality 0–9685
Debt / EquityFinancial leverage0.00x1.60x2.60x
Net DebtTotal debt minus cash-$13M$35.3B$599.0B
Cash & Equiv.Liquid assets$13M$7.2B$343.3B
Total DebtShort + long-term debt$12,137$42.5B$942.4B
Interest CoverageEBIT ÷ Interest expense-48.78x35.68x0.74x
LLY leads this category, winning 6 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

LLY leads this category, winning 5 of 6 comparable metrics.

A $10,000 investment in LLY five years ago would be worth $51,381 today (with dividends reinvested), compared to $1,735 for FORA. Over the past 12 months, LLY leads with a +40.7% total return vs FORA's +2.4%. The 3-year compound annual growth rate (CAGR) favors LLY at 35.1% vs FORA's -2.5% — a key indicator of consistent wealth creation.

MetricFORA logoFORAForian Inc.LLY logoLLYEli Lilly and Com…JPM logoJPMJPMorgan Chase & …
YTD ReturnYear-to-date+2.4%+2.0%+0.8%
1-Year ReturnPast 12 months+2.4%+40.7%+20.9%
3-Year ReturnCumulative with dividends-7.3%+146.7%+138.8%
5-Year ReturnCumulative with dividends-82.7%+413.8%+135.5%
10-Year ReturnCumulative with dividends-90.5%+1449.6%+481.2%
CAGR (3Y)Annualised 3-year return-2.5%+35.1%+33.7%
LLY leads this category, winning 5 of 6 comparable metrics.

Risk & Volatility

Evenly matched — FORA and JPM each lead in 1 of 2 comparable metrics.

FORA is the less volatile stock with a 0.21 beta — it tends to amplify market swings less than JPM's 0.87 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. JPM currently trades 96.2% from its 52-week high vs FORA's 80.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricFORA logoFORAForian Inc.LLY logoLLYEli Lilly and Com…JPM logoJPMJPMorgan Chase & …
Beta (5Y)Sensitivity to S&P 5000.21x0.52x0.87x
52-Week HighHighest price in past year$2.71$1182.73$338.09
52-Week LowLowest price in past year$1.64$623.78$269.72
% of 52W HighCurrent price vs 52-week peak+80.1%+92.8%+96.2%
RSI (14)Momentum oscillator 0–10063.857.272.1
Avg Volume (50D)Average daily shares traded40K2.6M7.4M
Evenly matched — FORA and JPM each lead in 1 of 2 comparable metrics.

Analyst Outlook

JPM leads this category, winning 2 of 2 comparable metrics.

Analyst consensus: LLY as "Buy", JPM as "Buy". Consensus price targets imply 15.8% upside for LLY (target: $1271) vs 4.5% for JPM (target: $340). For income investors, JPM offers the higher dividend yield at 1.83% vs LLY's 0.55%.

MetricFORA logoFORAForian Inc.LLY logoLLYEli Lilly and Com…JPM logoJPMJPMorgan Chase & …
Analyst RatingConsensus buy/hold/sellBuyBuy
Price TargetConsensus 12-month target$1271.24$339.75
# AnalystsCovering analysts4561
Dividend YieldAnnual dividend ÷ price+0.5%+1.8%
Dividend StreakConsecutive years of raises1115
Dividend / ShareAnnual DPS$6.00$5.95
Buyback YieldShare repurchases ÷ mkt cap+0.6%+0.4%+3.8%
JPM leads this category, winning 2 of 2 comparable metrics.
Key Takeaway

LLY leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). JPM leads in 2 (Valuation Metrics, Analyst Outlook). 1 tied.

Best OverallEli Lilly and Company (LLY)Leads 3 of 6 categories
Loading custom metrics...

FORA vs LLY vs JPM: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is FORA or LLY or JPM a better buy right now?

For growth investors, Forian Inc.

(FORA) is the stronger pick with 50. 1% revenue growth year-over-year, versus 3. 3% for JPMorgan Chase & Co. (JPM). JPMorgan Chase & Co. (JPM) offers the better valuation at 16. 2x trailing P/E (14. 6x forward), making it the more compelling value choice. Analysts rate Eli Lilly and Company (LLY) a "Buy" — based on 45 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — FORA or LLY or JPM?

On trailing P/E, JPMorgan Chase & Co.

(JPM) is the cheapest at 16. 2x versus Eli Lilly and Company at 47. 8x. On forward P/E, JPMorgan Chase & Co. is actually cheaper at 14. 6x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: JPMorgan Chase & Co. wins at 0. 83x versus Eli Lilly and Company's 1. 04x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

03

Which is the better long-term investment — FORA or LLY or JPM?

Over the past 5 years, Eli Lilly and Company (LLY) delivered a total return of +413.

8%, compared to -82. 7% for Forian Inc. (FORA). Over 10 years, the gap is even starker: LLY returned +1450% versus FORA's -90. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — FORA or LLY or JPM?

By beta (market sensitivity over 5 years), Forian Inc.

(FORA) is the lower-risk stock at 0. 21β versus JPMorgan Chase & Co. 's 0. 87β — meaning JPM is approximately 313% more volatile than FORA relative to the S&P 500. On balance sheet safety, Forian Inc. (FORA) carries a lower debt/equity ratio of 0% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.

05

Which is growing faster — FORA or LLY or JPM?

By revenue growth (latest reported year), Forian Inc.

(FORA) is pulling ahead at 50. 1% versus 3. 3% for JPMorgan Chase & Co. (JPM). On earnings-per-share growth, the picture is similar: Eli Lilly and Company grew EPS 96. 0% year-over-year, compared to 1. 5% for JPMorgan Chase & Co.. Over a 3-year CAGR, LLY leads at 31. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — FORA or LLY or JPM?

Eli Lilly and Company (LLY) is the more profitable company, earning 31.

7% net margin versus -9. 5% for Forian Inc. — meaning it keeps 31. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LLY leads at 45. 6% versus -8. 2% for FORA. At the gross margin level — before operating expenses — LLY leads at 83. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is FORA or LLY or JPM more undervalued right now?

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, JPMorgan Chase & Co. (JPM) is the more undervalued stock at a PEG of 0. 83x versus Eli Lilly and Company's 1. 04x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, JPMorgan Chase & Co. (JPM) trades at 14. 6x forward P/E versus 30. 0x for Eli Lilly and Company — 15. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for LLY: 15. 8% to $1271. 24.

08

Which pays a better dividend — FORA or LLY or JPM?

In this comparison, JPM (1.

8% yield), LLY (0. 5% yield) pay a dividend. FORA does not pay a meaningful dividend and should not be held primarily for income.

09

Is FORA or LLY or JPM better for a retirement portfolio?

For long-horizon retirement investors, Eli Lilly and Company (LLY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

52), 0. 5% yield, +1450% 10Y return). Both have compounded well over 10 years (LLY: +1450%, FORA: -90. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between FORA and LLY and JPM?

These companies operate in different sectors (FORA (Healthcare) and LLY (Healthcare) and JPM (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: FORA is a small-cap high-growth stock; LLY is a mega-cap high-growth stock; JPM is a large-cap deep-value stock. LLY, JPM pay a dividend while FORA does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.